Good Vita / The learning library

GHK-Cu

A copper-containing peptide discussed in skin and injectable-product marketing.

Educational information only. No medical advice or treatment recommendations.

← Back to the full library

Research compounds Laboratory study Skin research

Also discussed as: Copper peptide

What it is and how it works

GHK-Cu is a copper complex of the tripeptide glycine-histidine-lysine. In the cited fibroblast-culture experiment it stimulated collagen synthesis. Cells growing in a laboratory are useful for studying mechanisms, but do not reproduce an entire person’s skin or response to an injected product.

Source for the mechanism context →

A closer look at the cited evidence

Laboratory study

This label describes the selected source below. It is not a complete ranking of the literature, a safety score, or an approval status.

Study or assessment
Maquart et al., 1988 — GHK-Cu and fibroblast collagen synthesis
Design
Cell-culture experiment.
Who or what was studied
Cultured fibroblasts; not a trial in people.
What was observed
The copper-peptide complex increased collagen synthesis under the experimental conditions.
Limits of interpretation
This selected study cannot establish an injectable treatment’s safety or demonstrate a visible cosmetic benefit in people. It does not summarize the entire topical literature.
Read the cited study or assessment →

What the evidence means

Evidence must match the formulation and route; a cosmetic claim cannot validate an injectable product.

Approval and regulatory context

An injectable research product should not be confused with an approved medicine or a topical cosmetic.

Safety and uncertainty

Injectable human safety data are limited.

What remains uncertain

A topical formulation, a laboratory reagent, and an injectable product answer different questions. Product-specific studies would be needed to connect a mechanism with a reliable clinical outcome for a given route.

These summaries are introductory and are not a complete account of the literature, adverse effects, contraindications, or interactions. Absence of a listed risk does not mean absence of risk. Different compounds, formulations, and routes cannot be treated as interchangeable.

Sources behind this overview

Read the source in its full context. Source links support the overview; they do not imply endorsement of this library by the source organization.

Start Your Assessment